Alzheimer’s disease (AD) is a chronic and progressive neurodegenerative disease. It is the most common cause of dementia in the elderly, responsible for roughly 70% of late-onset cases. The disease’s fundamental mechanisms are still unknown fully, but typical pathological hallmarks include an alteration of a protein structure (Amyloid-beta (Aβ)), that causes an extracellular deposition of the Amyloid plaques and also may cause by hyperphosphorylation of tau protein, which leads to an intracellular accumulation of neurofibrillary tangles NFTs then these aggregates become neurotoxic, and leads to memory loss and cognitive impairment. Only five drugs have been approved by the FDA as medications that only slow down the disease’s progress. İmplantable matrix drug delivery systems can be one of the most promising methods of ensuring continuous drug delivery with first-order release kinetics, these systems have the ability to deliver a specific amount of drug within a certain period of time reducing the side effects since they can deliver the drug effectively with low concentrations and increase the patient compliance and that would be very helpful for Alzheimer patients who may forget to take their drugs since they have problems related to the memory. In this study, we aimed to demonstrate a significant effect on treating and preventing Alzheimer’s disease by using a combination of curcumin (Cur), ferulic acid (FA), and phosphatidylserine (PS) not alone but as a combination due to their neuroprotective activities, As well as applying this combination to an implantable matrix drug delivery device which is designed to be biodegradable after it has achieved its function overcoming limitations such as BBB and enzyme metabolism that limit the absorption of drugs.

Keywords:

Alzheimer’s disease; Amyloid-beta (Aβ); Blood-brain barrier BBB; curcumin; ferulic acid; phosphatidylserine; biodegradable implants